RWM
LRMR icon

Rialto Wealth Management’s Larimar Therapeutics LRMR Stock Holding History

Rialto Wealth Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$793 Hold
260
– – ﹤0.01% 1464
2026
Q1 		$1.17K Hold
260
– – ﹤0.01% 1050
2025
Q4 		$991 Hold
260
– – ﹤0.01% 1004
2025
Q3 		$840 Hold
260
– – ﹤0.01% 993
2025
Q2 		$752 Buy
+260
New +$602 ﹤0.01% 967

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Rialto Wealth Management's LRMR Position: Q2 2026 in Review

Rialto Wealth Management held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 260 shares worth $793. The position accounts for ﹤0.01% of the portfolio, ranked #1464.

Rialto Wealth Management first reported a position in LRMR in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.17K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Rialto Wealth Management held 260 shares of Larimar Therapeutics worth $793 as of Q2 2026.
  • Rialto Wealth Management left its Larimar Therapeutics share count unchanged in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1464 holding.
  • Rialto Wealth Management first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Rialto Wealth Management's Larimar Therapeutics position peaked at $1.17K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.